| Bioactivity | Metixene (Piperidine) is an anticholinergic and antiparkinsonian agent. Metixene potently inhibits binding of quinuclidinyl benzilate (QNB) with the muscarinic receptor, IC50 and Ki values of 55 nM and 15 nM, respectively. Metixene can be used for the research of parkinsonian[1][2][3]. |
| Invitro | Metixene can potentially inhibit the binding of QNB with the muscarinic receptor， IC50 and Ki values of 55 nM and 15 nM, respectively[3]. |
| Name | Metixene |
| CAS | 4969-02-2 |
| Formula | C20H23NS |
| Molar Mass | 309.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Syvälahti EK, et al. Effects of antiparkinsonian drugs on muscarinic receptor binding in rat brain, heart and lung. Pharmacol Toxicol. 1988 Feb;62(2):90-4. [2]. J. Hagenah, et al. Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: further clinical evidence. , 106(3-4), 301–307. doi:10.1007/s007020050159 [3]. S L Levin, et al. Dualism in the effect of cholinolytics upon the human parotid gland deprived of parasympathetic control. Int J Clin Pharmacol Res. 1986;6(5):429-39. |